Our brainwave combinations are based on 15 years of clinical research. Early clinical results are promising. In a pilot study of 10 Azheimer’s Disease patients, we significantly corrected key brainwave markers that characterize the disease. Our unique, patent-pending device connects to any MP3 player (e.g iPhone, Zune) and allows a consumer to experience MBS's proprietary brainwave therapy while listening to their own music.